New CTC trial results presented at ASCO


New CTC trial results, including a simple skin cancer preventive, presented at American Society of Clinical Oncology meeting

Andrew Martin, CTC senior biostatistician, presented results of the ONTRAC study at the meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, 30 May.

ONTRAC was a phase III trial showing that oral nicotinamide significantly reduced the formation of new nonmelanoma skin cancers compared with placebo in patients with severely sun-damaged skin. It was a University of Sydney study led by Dr Diona Damian from the Department of Dermatology.

This presentation was a highlight of the meeting and its important results have been reported widely.

The results of the CTC's trials, CABARET (advanced glioblastoma, brain cancer) and INTEGRATE (oesophagogastric cancer) were also announced at ASCO.


References to all CTC ASCO presentations follow. Full details of each presentation are available from the search page here.

Bamias A, Dimopoulos MA, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Lee C, Gebski V, Pujade-Lauraine E. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.

Barbour A, O'Rourke N, Chandrasegaram MD, Chua YJ, Kench J, Samra JS, Pavlakis N, Haghighi KS, Yip S, Fawcett J, Donoghoe M, Walker K, Burge ME, Gananadha S, Harris M, Aghmesheh M, Joubert WL, Gebski V, Simes J, Goldstein D. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP study.

Chan D, Goldstein D, Sjoquist KM, Pavlakis N. Antiangiogenic agents in metastatic oesophago-gastric cancer: a systematic review and meta-analysis.

Chin V, Nagrial A, Chantrill L, Sjoquist K, O'Connor C, Pajic M, Biankin A, Yip D. Targeted therapies in the treatment of advanced pancreatic adenocarcinoma: a systematic review and meta-analysis of randomized trials. Davis ID, Stockler MR, Martin AJ, Marchesin V, Deignan O, McDermott R, Parulekar WR, North SA, Graham B, Long AP, Roncolato FT, Yip S, Hague W, Dazo CC, X., Sweeney C. Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET trial (ANZUP 1304).

Duchesne GM, Bassett J, D'Este C, Frydenberg M, Ledwich L, Millar JL, Milne RLS, R., Spry N, Stockler MR, Syme R, Turner S, Tai KH, Woo H, TROG & Cancer Council Victoria. TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial.

Friedlander M, Stockler MR, O'Connell R, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Pignata S, Donnellan PP, Oza AM, Avall-Lundqvist E, Berek JS, Sjoquist KM, Gillies K, Butow P, King MT. Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer?: Symptom burden and outcomes in patients with platinum resistant/refractory and potentially platinum sensitive recurrent ovarian cancer receiving ≥3 lines of chemotherapy (≥3)-the Gynecologic Cancer Intergroup Symptom Benefit study.

Gibbs P, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Gebski V, Van Buskirk M, Van Hazel G, SIRFLOX Study Group. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy ± bevacizumab in patients with metastatic colorectal cancer.

Hovey EJ, Field KM, Rosenthal M, Nowak AK, Cher L, Wheeler H, Barnes E, Phal P, Livingstone A, Sawkins K, Simes J, COGNO CABARET Investigators. Continuing or ceasing bevacizumab at disease progression: results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.

Lee C, Davies LC, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Throngprasert S, Fukuoka M, Gralla RJ, Gebski V, Mok T, Yang JCH. The impact on overall survival of first-line gefitinib and erlotinib and of clinical factors in advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations based on meta-analysis of 1,231 patients enrolled in 6 major randomized trials.

Lee C, Gibbs E, ROncolato FT, Davies LC, Le Maignan C, Meier W, Lanza MAA, Rosenberg P, Marchetti C, Vergote I, Witteveen P, Bamias A, Serra S, Provencal J, De Rauglaudre G, Gebski V, Friedlander M, Pujade-Lauraine E. Development and validation of a prognostic nomogram to predict overall survival in platinum-resistant ovarian cancer: An AURELIA substudy.

Martin AJ, Chen A, Choy B, Fernandez-Penas F, Halliday GM, Dalziell R, McKenzie C, Scolyer RA, Dhillon HM, Vardy JL, St George G, Chinniah N, Damian DL. Oral nicotinamide to reduce actinic cancer: a phase 3 double-blind randomized controlled trial.

Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang YK, Bang YJ, O'Callaghan CJ, tebbutt NC, Rha SY, Cho JY, Lipton LR, Burnell MJ, Alcindor T, Strickland A, Kim JW, Yip S, SImes J, Zalcberg J, Goldstein D. INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)-final overall and subgroup results.

Roncolato F, O'Connell RL, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Pignata S, Donnellan PP, Oza AM, Avall-Lundqvist E, Berek JS, Sjoquist KM, Gillies K, Butow P, Stockler MR, King MT, Friedlander M. Baseline predictors of early treatment failure in patients with platinum resistant/refractory and potentially platinum sensitive (≥3) recurrent ovarian cancer receiving ≥3 lines of chemotherapy: the Gynaecologic Cancer Intergroup Symptom Benefit Study.

Sjoquist KM, Bokemeyer C, Renfro LA, Simes J, Tebbutt NC, S.J. C, Adams R, Punt CJA, Cutsem EV, Douillard JY, Hecht R, Heinemann V, Sougklakos I, Diaz-Rubio E, Porschen R, Meyers JP, Gonsalves WI, Sargent DJ, De Gramont A, Zalcberg J. Calculators for overall survival and progression-free survival in metastatic colorectal cancer: construction from 19,678 ARCAD patients.

Trillsch F, Mahner S, Hilpert F, Davies LC, Garcia-Martinez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Lee C, Gebski V, Pujade-Lauraine E. Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.

Williams SG, Davis ID, Sweeney C, Stockler MR, Martin AJ, Marchesin V, Deignan O, McDermott R, Long AP, Roncolato FT, Yip S, Hague W, Tu E, Coskinas X, Nguyen PL. Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: the ANZUP ENZARAD trial (ANZUP 1303).

Zdenkowski N, Green M, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Gebski V, Veillard AS, Davies LC, Thornton R, Fong A, Reaby LL, Forbes JF, Australia and New Zealand Breast Cancer Trials Group. Final analysis of a randomized comparison of letrozole vs observation as late reintroduction of adjuvant endocrine therapy for postmenopausal women with hormone receptor positive breast cancer after completion of prior adjuvant endocrine therapy: ANZBCTG 0501 (LATER). 

2 June 2015